140 related articles for article (PubMed ID: 9698539)
1. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu.
Roh H; Pippin J; Boswell C; Drebin JA
J Surg Res; 1998 Jun; 77(1):85-90. PubMed ID: 9698539
[TBL] [Abstract][Full Text] [Related]
2. HER2/neu antisense targeting of human breast carcinoma.
Roh H; Pippin JA; Green DW; Boswell CB; Hirose CT; Mokadam N; Drebin JA
Oncogene; 2000 Dec; 19(53):6138-43. PubMed ID: 11156527
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu.
Roh H; Pippin J; Drebin JA
Cancer Res; 2000 Feb; 60(3):560-5. PubMed ID: 10676637
[TBL] [Abstract][Full Text] [Related]
4. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
[TBL] [Abstract][Full Text] [Related]
5. Expression of a truncated 100 kDa HER2 splice variant acts as an endogenous inhibitor of tumour cell proliferation.
Aigner A; Juhl H; Malerczyk C; Tkybusch A; Benz CC; Czubayko F
Oncogene; 2001 Apr; 20(17):2101-11. PubMed ID: 11360194
[TBL] [Abstract][Full Text] [Related]
6. HER2/neu increases the expression of Wilms' Tumor 1 (WT1) protein to stimulate S-phase proliferation and inhibit apoptosis in breast cancer cells.
Tuna M; Chavez-Reyes A; Tari AM
Oncogene; 2005 Feb; 24(9):1648-52. PubMed ID: 15674342
[TBL] [Abstract][Full Text] [Related]
7. Targeting human breast cancer cells that overexpress HER-2/neu mRNA by an antisense iron responsive element.
Yan DH
Biochem Biophys Res Commun; 1998 May; 246(2):353-8. PubMed ID: 9610362
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancer.
Rait AS; Pirollo KF; Rait V; Krygier JE; Xiang L; Chang EH
Cancer Gene Ther; 2001 Oct; 8(10):728-39. PubMed ID: 11687896
[TBL] [Abstract][Full Text] [Related]
9. Temporary ex vivo inhibition of the expression of the human oncogene HER2 (NEU) by a triple helix-forming oligonucleotide.
Porumb H; Gousset H; Letellier R; Salle V; Briane D; Vassy J; Amor-Gueret M; Israƫl L; Taillandier E
Cancer Res; 1996 Feb; 56(3):515-22. PubMed ID: 8564964
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of p185c-erbB-2 proto-oncogene expression by antisense oligodeoxynucleotides down-regulates p185-associated tyrosine-kinase activity and strongly inhibits mammary tumor-cell proliferation.
Brysch W; Magal E; Louis JC; Kunst M; Klinger I; Schlingensiepen R; Schlingensiepen KH
Cancer Gene Ther; 1994 Jun; 1(2):99-105. PubMed ID: 7621247
[TBL] [Abstract][Full Text] [Related]
11. Human manganese superoxide dismutase suppresses HER2/neu-mediated breast cancer malignancy.
Chuang TC; Liu JY; Lin CT; Tang YT; Yeh MH; Chang SC; Li JW; Kao MC
FEBS Lett; 2007 Sep; 581(23):4443-9. PubMed ID: 17719580
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated cytotoxicity in breast cancer cells with high-expressing HER2/neu.
Shiu LY; Liang CH; Huang YS; Sheu HM; Kuo KW
Cell Biol Toxicol; 2008 Jan; 24(1):1-10. PubMed ID: 17885815
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of growth of human breast carcinoma cells by an antisense oligonucleotide targeted to the transferrin receptor gene.
Yang DC; Jiang XP; Elliott RL; Head JF
Anticancer Res; 2001; 21(3B):1777-87. PubMed ID: 11497259
[TBL] [Abstract][Full Text] [Related]
14. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis.
Afonja O; Juste D; Das S; Matsuhashi S; Samuels HH
Oncogene; 2004 Oct; 23(49):8135-45. PubMed ID: 15361828
[TBL] [Abstract][Full Text] [Related]
15. [Down regulation of HER2/neu expression by adenovirus E1A and its anti-tumor activity].
Lu H; Qin H; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2000 Sep; 22(5):370-3. PubMed ID: 11778270
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event.
Hanna W; Nofech-Mozes S; Kahn HJ
Breast J; 2007; 13(2):122-9. PubMed ID: 17319852
[TBL] [Abstract][Full Text] [Related]
17. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis.
Xu FJ; Stack S; Boyer C; O'Briant K; Whitaker R; Mills GB; Yu YH; Bast RC
Clin Cancer Res; 1997 Sep; 3(9):1629-34. PubMed ID: 9815853
[TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
19. Treatment of meningeal breast cancer xenografts in the rat using an anti-p185/HER2 antibody.
Bergman I; Barmada MA; Griffin JA; Slamon DJ
Clin Cancer Res; 2001 Jul; 7(7):2050-6. PubMed ID: 11448923
[TBL] [Abstract][Full Text] [Related]
20. Her-2/neu oncogene expression in Puerto Rican females with breast cancer.
Peredo R; Sastre G; Serrano J; Hunter Mellado R
Cell Mol Biol (Noisy-le-grand); 2001 Sep; 47(6):1025-32. PubMed ID: 11785652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]